Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.
复制标题
RAD51 表达的定量成像作为卵巢癌铂类耐药的标志物。
DOI：
10.15252/emmm.202013366
复制
发表时间：
2021-05-07
影响因子：
11.1
通讯作者：
Jeyasekharan AD
中科院分区：
文献类型：
--
作者：
Hoppe MM;Jaynes P;Wardyn JD;Upadhyayula SS;Tan TZ;Lie S;Lim DGZ;Pang BNK;Lim S;P S Yeong J;Karnezis A;Chiu DS;Leung S;Huntsman DG;Sedukhina AS;Sato K;Topp MD;Scott CL;Choi H;Patel NR;Brown R;Kaye SB;Pitt JJ;Tan DSP;Jeyasekharan AD
Early relapse after platinum chemotherapy in epithelial ovarian cancer (EOC) portends poor survival. A‐priori identification of platinum resistance is therefore crucial to improve on standard first‐line carboplatin–paclitaxel treatment. The DNA repair pathway homologous recombination (HR) repairs platinum‐induced damage, and the HR recombinase RAD51 is overexpressed in cancer. We therefore designed a REMARK‐compliant study of pre‐treatment RAD51 expression in EOC, using fluorescent quantitative immunohistochemistry (qIHC) to overcome challenges in quantitation of protein expression in situ. In a discovery cohort (n = 284), RAD51‐High tumours had shorter progression‐free and overall survival compared to RAD51‐Low cases in univariate and multivariate analyses. The association of RAD51 with relapse/survival was validated in a carboplatin monotherapy SCOTROC4 clinical trial cohort (n = 264) and was predominantly noted in HR‐proficient cancers (Myriad HRDscore < 42). Interestingly, overexpression of RAD51 modified expression of immune‐regulatory pathways in vitro, while RAD51‐High tumours showed exclusion of cytotoxic T cells in situ. Our findings highlight RAD51 expression as a determinant of platinum resistance and suggest possible roles for therapy to overcome immune exclusion in RAD51‐High EOC. The qIHC approach is generalizable to other proteins with a continuum instead of discrete/bimodal expression. Quantitative immunohistochemistry (qIHC) reveals that high expression of the DNA repair protein RAD51 in epithelial ovarian cancer (EOC) is associated with early relapse after platinum chemotherapy, and also with decreased cytotoxic T‐cell infiltration into tumors.
登录
查看更多内容
影响因子：
14.9
作者：
Fischer M;Grossmann P;Padi M;DeCaprio JA
通讯作者：
DeCaprio JA
影响因子：
16.6
作者：
Domcke, Silvia;Sinha, Rileen;Levine, Douglas A.;Sander, Chris;Schultz, Nikolaus
通讯作者：
Schultz, Nikolaus
RAD51的高级表达是非小细胞肺癌患者生存的独立预后标志。
影响因子：
8.8
作者：
Qiao, GB;Wu, YL;Yang, XN;Zhong, WZ;Xie, D;Guan, XY;Fischer, D;Kolberg, HC;Kruger, S;Stuerzbecher, HW
通讯作者：
Stuerzbecher, HW
影响因子：
5.3
作者：
Gachechiladze, Mariam;Skarda, Josef;Joerger, Markus
通讯作者：
Joerger, Markus
影响因子：
45.3
作者：
MARKMAN, M;ROTHMAN, R;LEWIS, JL
通讯作者：
LEWIS, JL